Tamoxifen Pharmacogenetics and Prediction of Breast Cancer Relapse After Administration of Tamoxifen Matthew P. Goetz, MD Assistant Professor of Oncology.

Slides:



Advertisements
Similar presentations
Oncotype DX® Breast Cancer Assay Clinical Data Review
Advertisements

Breast Cancer Systemic Therapy for Early Stage Disease
Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.
History of the randomized evidence on early breast cancer overall survival: Radiation vs no radiation after mastectomy L. Vakaet 2006.
Pharmacogenetics and the Management of Breast Cancer: Optimization of Tamoxifen Therapy Mark E. Sobel, M.D., Ph.D. Executive Officer American Society for.
Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent.
Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.
Robertson JFR et al. J Clin Oncol 2009;27(27):
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer N Engl J Med 2011 Dec 7. Presenstor : CR 周益聖 Instructor : VS 趙大中 財團法人台灣癌症臨床研究發展基金會.
INIBITORI DELL’AROMATASI
Breast Cancer Tumor Board Chair Harold Burstein, MD, PhD Faculty Jennifer Bellon, MD Mehra Golshan, MD.
PREOPERATIVE PLASMA CONCENTRATION OF MMP-9/TIMP-1 COMPLEXES IS NOT ASSOCIATED WITH DISEASE OUTCOME IN PRIMARY BREAST CANCER (N=483) Anne-Sofie Schrohl.
Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Department of Surgery, United Christian Hospital Aromatase Inhibitors Current Use in Breast Cancer JHGR 16 Jan 2005 Dr. Sharon Chan Department of Surgery,
1 The Role of the Oncotype DX ® Breast Cancer Assay in the Neoadjuvant Setting.
Description of fracture with endocrine therapy use in older breast cancer survivors in a population-based setting Taryn Becker 123, Geoff Anderson 123,
Long-Term Effects of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years After Diagnosis of Oestrogen Receptor- Positive Breast Cancer:
Pharmacogenetics of Tamoxifen An FDA Perspective
These slides were released by the speaker for internal use by Novartis.
Clinicaloptions.com/oncology FRANCESCO BOCCARDO Professore Ordinario di Oncologia Medica, Università di Genova Direttore Oncologia Medica B IST.Genova.
Wildiers H, et al. Lancet Oncol. 2007;8:1101. Breast Cancer in Elderly (>65 Years) Recommendations of the International Society of Geriatric Oncology Surgical.
Tang G et al. Proc SABCS 2010;Abstract S4-9.
HERA: KEY DESIGN ELEMENTS, RESULTS AND FUTURE PLANS NSABP 17 SEPTEMBER 2005 Brian Leyland-Jones Minda De Gunzberg Professor of Oncology, McGill University,
Outcome According to CYP2D6 Genotype Among Postmenopausal Women with Endocrine-Responsive Early Invasive Breast Cancer Randomized in the BIG 1-98 Trial.
Sgroi DC et al. Proc SABCS 2012;Abstract S1-9.
These slides were released by the speaker for internal use by Novartis
Dubsky P et al. Proc SABCS 2012;Abstract S4-3.
Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.
Best first ? The ATAC completed treatment analysis Professor Jack Cuzick Wolfson Institute of Preventive Medicine, London, UK.
Principles of Hormonal Therapy Justus Apffelstaedt University of Stellenbosch These Power Point presentations are free to download only for academic purposes,
Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis Daniel J. Sargent,
HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF.
San Antonio Breast Cancer Symposium 2012 Helen K. Chew, MD, FACP Professor of Medicine.
Start or Switch?: Latest data from ABCSG/ARNO
Neoadjuvant SystemicTreatment Strategies for Breast Cancer Donald W. Northfelt, MD, FACP Professor of Medicine Mayo Clinic College of Medicine Associate.
Neoadjuvant Endocrine Treatment in Breast Cancer Giorgio Mustacchi Centro Oncologico Università di Trieste.
Published online July 24, Aromatase inhibitors versus tamoxifen in early breast.
Tamoxifen, Endoxifen, and CYP2D6 Sally Usdin Yasuda, MS, PharmD Senior Reviewer, Division of Clinical Pharmacology 1 Office of Clinical Pharmacology Center.
DL Wickerham MD Deputy Chairman NRG Oncology Oct 5, 2015
Ductal Carcinoma in Situ with Microinvasion: Prognostic Implications, Long-term Outcomes, and Role of Axillary Evaluation Rahul R. Parikh, MD 1, Bruce.
Aubert RE et al. ASCO 2009; Abstract CRA508. (Oral Presentation)
Copyright © 2010, Research To Practice, All rights reserved. Current Clinical and Future Developmental Paradigms Involving Molecular Pathways in Breast.
Breast Cancer in the Women’s Health Initiative Trial of Estrogen Plus Progestin For the WHI Investigators Rowan T Chlebowski, MD., Ph.D.
Breast cancer 5 year survival rates (UK, 1975) by stage at diagnosis.
These slides are intended to educate the scientific and medical community and keep them fully informed about continuing progress, as is their right, stipulated.
A Comparison of Fulvestrant 500 mg with Anastrozole as First-line Treatment for Advanced Breast Cancer: Follow-up Analysis from the FIRST Study Robertson.
Extended adjuvant treatment with anastrozole: results from the ABCSG Trial 6a R Jakesz, H Samonigg, R Greil, M Gnant, M Schmid, W Kwasny, E Kubista, B.
Breast Cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast – “National Breast Cancer Foundation” The American.
Anastrozole (‘Arimidex’): a new standard of care?
‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: Completed Treatment Analysis.
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
Lectures inEarly Breast Cancer A PowerPoint slide set based on images from: Lectures in Early Breast Cancer Part 3: Adjuvant Therapy in Early Breast Cancer.
Treatment Options for Postmenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Recent Trials and Future Directions Harold Burstein,
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.
CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.
J Clin Oncol 30: R2 윤경한 / Prof. 김시영 Huan Jin, Dongsheng Tu, Naiqing Zhao, Lois E. Shepherd, and Paul E. Goss.
MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.
Angelo Di Leo “Sandro Pitigliani” Medical Oncology Department Hospital of Prato Istituto Toscano Tumori, Prato, Italy Adjuvant hormone therapy in pre-menopausal.
Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.
Adjuvant Hormonal Therapy for Premenopausal Women
JOURNAL OF CLINICAL ONCOLOGY 25:
Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer.
THBT neoadjuvant endocrine therapy is to be used in post-menopausal breast cancer woman Antonino Grassadonia Università «G. D’Annunzio» – Chieti-Pescara.
Figure 2. A consort diagram showing the flowchart of the trial
Circulating Tumor Cells and Late Recurrence of Breast Cancer
Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results.
Effect of Obesity on Prognosis after Early Breast Cancer
ABSTRACT ABCSG 6a MA17-1 MA.17R NSABP B-33. Extended Adjuvant Therapy With Aromatase Inhibitor Among Postmenopausal Breast Cancer.
20-Year Risks of Breast-Cancer Recurrence
Presentation transcript:

Tamoxifen Pharmacogenetics and Prediction of Breast Cancer Relapse After Administration of Tamoxifen Matthew P. Goetz, MD Assistant Professor of Oncology Mayo Clinic College of Medicine CP David Flockhart, MD, PhD Consortium on Breast Cancer Pharmacogenomics (COBRA) Pharmacogenomics Research Network

Breast Cancer 2006 (USA) Invasive Breast Cancer: 212,920 New Cases Ductal Carcinoma in Situ: 61,980 Cases 2/3 are estrogen positive—Candidates for hormonal therapy Jemal A, et al. CA Cancer J Clin 2006;56;106-30

Tamoxifen The most important drug worldwide for hormone receptor positive breast cancer Approved by the FDA for treatment of High-risk patients DCIS Pre and Postmenopausal breast cancer Metastatic disease Most commonly used hormonal therapy in early and advanced male breast cancer CP

Tamoxifen and Breast Cancer FDA-Approved Indications Postmenopausal Metastatic DCIS ‘86 Adjuvant Postmenopausal Node+ Premenopausal Metastatic ‘89‘90 Adjuvant Node-negative ‘93 Male Metastatic “Prevention” ‘98

CP EBCTCG: Lancet 365:1687, 2005 Recurrence (%) Years Control 45-0% Control 45-0% About 5 years of tamoxifen 33.2% About 5 years of tamoxifen 33.2% Tamoxifen (for ~5 yrs) in Early Breast Cancer Oxford Meta-analysis* *10,386 women Hazard Ratio (Control/Tamoxifen) = ~1.69

Adjuvant Hormonal Therapy: Designs of Recent Major Trials CP Switching Tamoxifen Aromatase Inhibitor Placebo Initial Adjuvant Therapy 5 yr 2-3 yr 5 yr ~5 yr Extended Adjuvant Therapy R R R R R R DFS HR 0.57 DFS HR

Adjuvant hormonal therapy Pre-menopausal Tamoxifen for 5 years Postmenopausal Aromatase inhibitor for 5 years or… Tamoxifen for 2-3 yrs followed by an AI

ATAC: Recurrences before 2.5 years Proportion with recurrence (%) HR95% CIp-value AN vs TAM – * Censoring non-BC deaths before recurrence Time to event (months) No. of Pts. at risk AN TAM Anastrozole Tamoxifen Howell A, EBCC Hamburg Absolute difference 1.6%

Is there a better way to identify patients for whom tamoxifen or anastrozole would be the preferred drug for initial adjuvant endocrine therapy?

Tamoxifen Metabolic Pathway Jin, Y. et al. J Natl Cancer Inst 2005;97:30-39 CP

Endoxifen and 4-OH-Tamoxifen are Equipotent as Inhibitors of Estrogen Stimulated Cell Proliferation Concentration Cell Growth Johnson MD, et al: Breast Cancer Res Treat 85:151-9, 2004

Endoxifen and 4-OH tamoxifen Same potency in ER binding 1 Suppression of ER-dependent MCF-7 proliferation 2 global ER-responsive gene expression 3 Different Endoxifen concentrations 10 fold higher than 4- hydroxy tamoxifen 4 1. Johnson et al. Breast Cancer Res Treat Lim YC, Cancer Chemother Pharmacol 2005;. 3. Lim YC, et al. J Pharmacol Exp Ther 2006;In Press. 4. Stearns Vet al. J Natl Cancer Inst 2003.

Tamoxifen Metabolic Pathway CP Jin Y et al: J Natl Cancer Inst 97:30, 2005

CYP2D6 Genotype and Endoxifen CP Jin Y et al: J Natl Cancer Inst 97:30, 2005 CYP2D6*4 (most common genetic variant associated with the CYP2D6 poor metabolizer state) P<0.001, r 2 =0.24 Plasma Endoxifen (nM)

NCCTG CP RANDOMIZATIONRANDOMIZATION Postmenopausal women Early ER + breast cancer 541 women accrued 5 years tamoxifen + 1 year fluoxymesterone (n=285) 5 years of tamoxifen (n=256) Ingle et al. Breast Cancer Res Treat Mar 15

NCCTG Surgically resected stage I-III breast cancer All tumors were estrogen receptor positive ≥10 fmol/mg cytosol protein positive or positive by immunohistochemical assay No adjuvant chemotherapy allowed Median follow-up of 11 years Accrual completed in April 1995 No differences in RFS or OS Ingle et al. Breast Cancer Res Treat Mar 15

CYP2D6*4 Genotyping Tamoxifen monotherapy arm (256 patients) Formalin-fixed paraffin-embedded tumor blocks (223 patients) CYP2D6*4 (n=190) Wt/Wt – 137 (72%) Wt/*4 – 40 (21%) *4/*4 – 13 (7%) CP Goetz, Rae et al: J Clin Oncol 23:9312, 2005

% % Years after randomization CYP2D6 Wt/Wt Relapse-free Time CYP2D6 *4/Wt CP CYP2D6 *4/*4 P=0.030P=0.030 Goetz et al J Clin Oncol. 2005;23(36):

% % Years after randomization Relapse-free Survival CP CYP2D6 WT/WT CYP2D6 *4/WT P=0.020 CYP2D6 *4/*4 Goetz et al J Clin Oncol. 2005;23(36):

Incidence of Moderate or Severe Hot Flashes Genotype% of patients who developed moderate or severe hot flashes *CYP2D6 *4/*4 *CYP2D6 *4/WT or Wt/WT 0% 20% Goetz et al J Clin Oncol. 2005;23(36):

CYP2D6 *4 Genotype and Clinical Outcome (multivariate analysis) *4/*4 vs Wt/Wt or Wt/*4 Time to breast recurrence: HR* 1.85, p=0.176 Relapse-free survival: HR* 1.86, p=0.089 CP *Adjusted for nodal status, tumor size Goetz, Rae et al: J Clin Oncol 23:9312, 2005

Without Paroxetine With Paroxetine Stearns V, et al. J Natl Cancer Inst 2003;95(23):

Inhibition of CYP2D6 Affects Endoxifen Concentrations CP Jin Y et al: J Natl Cancer Inst 97:30, 2005 Wt/Wt, no inhibitor VenlafaxineSertralineParoxetine*4/*4, no inhibitor Plasma Endoxifen (nM)

CYP2D6 Inhibitors and Breast Cancer Relapse Paroxetine, fluoxetine, and venlafaxine significantly reduce the number and severity of hot flashes in tamoxifen-treated women % tamoxifen-treated patients are prescribed antidepressants for depression or hot flashes 4 Other commonly administered medications also inhibit CYP2D6 (amiodarone, doxepin, cimetidine) An analysis of CYP2D6 metabolism in tamoxifen treated patients is incomplete without accounting for CYP2D6 inhibitors CP Loprinzi CL et al. Lancet 2000;356:2059– Loprinzi CL, et al. J Clin Oncol 2002;20:1578– Stearns et al. JAMA 2003;289:2827– Love et al. Patterns of Care in Medical Oncology (2005)

NCCTG CP RANDOMIZATIONRANDOMIZATION Postmenopausal women Early ER + breast cancer 541 women accrued 5 years tamoxifen + 1 year fluoxymesterone (n=285) 5 years of tamoxifen (n=256) Ingle et al. Breast Cancer Res Treat Mar 15

Methods 225 Charts were reviewed at each randomizing site to ascertain medication history Potent CYP2D6 inhibitors: Fluoxetine and paroxetine Moderate CYP2D6 inhibitors: Sertraline, cimetidine, amiodarone, doxepin, ticlopidine, or haloperidol Duration of coadministration: <1, 1-2, 2-3, 3-4 and 4-5 years Statistics: Log rank test and Cox modeling CP

Methods CYP2D6 metabolism defined by *4 genotype and medication history Extensive CYP2D6 metabolism  Wt/Wt, no inhibitor Decreased CYP26 metabolism  Wt/*4  *4/*4  Any genotype and co-administration (yes/no) of a moderate or potent CYP2D6 inhibitor

Patient Characteristics Metabolizer status known n=180 Median age (range)68 (42-87) ER status (%)100 Tumor size (cm) <3 (%) 78  3 (%) 22 Positive nodes 0 (%) (%) (%) 7  10 (%) 4 Tumor grade 1 (%) 24 2 (%) 54 3 (%) 15 Unknown (%) 7 CP Goetz et al. Breast Cancer Res Treat (In press)

Results CP CYP2D6 metabolism determined in 180 pts (medication history 225 pts) Inhibitor status Potent inhibitors (n=3) Moderate inhibitors (n=10) Median duration of use 2-3 years Goetz et al. Breast Cancer Res Treat (In press)

Time to Breast Recurrence CP % Years after randomization P=0.015 Extensive Decreased n=115 n=65 Goetz et al. Breast Cancer Res Treat (In press)

Relapse-Free Survival CP % Years after randomization P=0.007 Extensive Decreased n=115 n=65 Goetz et al. Breast Cancer Res Treat (In press)

Overall Survival CP % Years after randomization P=0.082 Extensive Decreased n=115 n=65 Goetz et al. Breast Cancer Res Treat (In press)

Outcomes by Metabolizer Status Multivariate Analysis* Hazard ratio (relative to Outcomeextensive metabolizers)P value Time to breast recurrence1.91 ( )0.034 Relapse-free survival1.74 ( )0.017 Overall survival1.35 ( )0.223 CP *Adjusted for size, grade and nodal status, ER, PR, HER-2 Goetz et al. Breast Cancer Res Treat (In press)

Inhibition of CYP2D6 Affects Endoxifen Concentrations CP Jin Y et al: J Natl Cancer Inst 97:30, 2005 Wt/Wt, no inhibitor VenlafaxineSertralineParoxetine*4/*4, no inhibitor Plasma Endoxifen (nM)

CYP2D6 Metabolism by Genotype and Inhibitor Decreased CYP2D6 Metabolism Intermediate metabolizers: n=40  Wt/*4 and no inhibitor (n=32)  Wt/Wt and moderate inhibitor (n=8) Poor metabolizers: n=16  4/*4 (n=13)  Any genotype and potent inhibitor (n=3) Unknown: n=9  Wt/*4 without med history (n=7)  Unknown genotype and mod inhibitor (n=2) Goetz et al. Breast Cancer Res Treat (In press)

Time to Breast Recurrence CP % Years after randomization Log Rank P=0.019 EM IM PM n=115 n=40 n=16 Goetz et al. Breast Cancer Res Treat (In press)

Relapse-Free Survival CP % Years after randomization 2-year RFS EM 98% IM 92% PM 68% Log Rank P=0.009 EM IM PM n=115 n=40 n=16 Goetz et al. Breast Cancer Res Treat (In press)

Overall Survival CP % Years after randomization Log Rank P=0.145 EM IM PM n=115 n=40 n=16 Goetz et al. Breast Cancer Res Treat (In press)

Outcomes by Metabolizer Status Univariate Analysis Hazard ratio (relative to Outcomeextensive metabolizers)P value Time to breast recurrence PM3.20 ( )0.007 IM1.49 ( ) Relapse-free survival PM2.69 ( )0.005 IM1.63 ( )0.075 Overall survival PM2.00 ( )0.077 IM1.40 ( )0.240 CP Goetz et al. Breast Cancer Res Treat (In press)

ATAC: Smoothed Hazard Rates for Recurrence Hormone Receptor + patients Follow-up time (years) Anastrozole Tamoxifen 0 Annual hazard rates (%) Howell, et al San Antonio Breast Cancer Symposium

Hazard Rates for RFS by CYP2D6 Metabolizer Status (n=180) CP Hazard rates Years after randomization Decreased Extensive Goetz et al. Breast Cancer Res Treat (In press)

Conclusion In this trial, CYP2D6 metabolism was an independent predictor of clinical outcome in postmenopausal women with ER positive early breast cancer The effect of impaired metabolism was most marked in poor metabolizers Consistent with clinical data that tamoxifen activation to endoxifen is dependent upon CYP2D6 CP

Conclusion These data suggest that determination of CYP2D6 genotype may be of value in selecting adjuvant hormonal therapy and moderate/potent CYPY2D6 inhibitors should not be co-administered with tamoxifen CP

Acknowledgments Mayo Clinic Cancer Center North Central Cancer Treatment Group Pharmacogenetics Research Network COBRA : The Consortium for Breast Cancer Pharmacogenomics: Indiana University School of Medicine University of Michigan Johns Hopkins University Mayo Clinic Baylor College of Medicine Mayo Clinic Breast Cancer SPORE

CYP2D6 Individualized Adjuvant Hormonal Study Postmenopausal women ER positive breast cancer UM: Ultra-rapid Metabolizer EM: Extensive Metabolizer IM: Intermediate Metabolizer PM: Poor Metabolizer Standard of care (AI for 5 years) RANDOMIZERANDOMIZERANDOMIZERANDOMIZE EM, UM Tam (2.5 years) followed by AI (2.5 years) (n=1950) AI (5 years total) (n=1950) CYP2D6 Genotyping IM, PM CYP2D6 IM, and PM: heterozygous or homozygous for *3, *4, *5, *6, *7, *8, *11, *12